The (Busy!) Year in Review: The Emergence of Aldosterone Synthase Inhibitors for Difficult-to-Control Hypertension in 2025
The (Busy!) Year in Review: The Emergence of Aldosterone Synthase Inhibitors for Difficult-to-Control Hypertension in 2025
ASH2025 Update on Management of Anemia in Patients with Myelofibrosis
Revisiting the Safety Record of IL-17 Inhibitors: A Guide for Dermatologists
Endogenous Hypercortisolism: Beyond Weight Gain and Moon Facies
Late Breaking Clinical Trial Data from AHA 2025 on Approved and Emerging Lipid Lowering Therapies: Highlights Selected by the Experts
Late Breaking Clinical Trial Data from AHA 2025 on Approved and Emerging Lipid Lowering Therapies: Highlights Selected by the Experts
Late-Breaking Clinical Trial Data from AHA 2025 on Approved and Emerging Lipid-Lowering Therapies: Highlights Selected by the Experts
Update from AHA2025 on Management of ATTR-CM With TTR Stabilizers and Other Strategies
Update from AHA2025: New Data on Disease Modifying Therapy in the Management of ATTR Amyloidosis
AANEM 2025: Conference Review and Analysis for New Data on Emerging BAFF/APRIL Inhibitors for the Management of Patients with Generalized Myasthenia Gravis
Patient Self-Management of Acute PSVT: A Systematic Review of Etripamil Data from AHA25
AANEM 2025: Conference Review and Analysis for New Data on Emerging BAFF/APRIL Inhibitors for the Management of Patients with Generalized Myasthenia Gravis
The Nephrology Community’s Reception of New Phase 3 Data on Aldosterone Synthase Inhibitors for Difficult-to-Control Hypertension at ESC2025
The Nephrology Community’s Reception of New Phase 3 Data on Aldosterone Synthase Inhibitors for Difficult-to-Control Hypertension at ESC2025
Update on Management of Anaemia in Patients with Myelofibrosis
Update on Non-Statin Lipid-Lowering Therapies from ESC 2025
Update on CD19-Targeted CAR T-cell Therapy to Treat Severe Refractory Systemic Lupus Erythematosus (SLE)
The Potential for Targeted Inhibition of Factor XI/XIa to Provide Safe and Effective Protection from a Secondary Ischemic Noncardioembolic Stroke
Update on CD19-Targeted CAR T-cell Therapy to Treat Severe Refractory Systemic Lupus Erythematosus (SLE)